Glyoxalase-I (GLO1), also known as lactoylglutathione lyase or methylglyoxalase, is an enzyme that plays a crucial role in the detoxification of methylglyoxal (MG), a cytotoxic by-product of glycolysis. This enzyme is part of the glyoxalase system, which includes Glyoxalase-I and Glyoxalase-II (GLO2), and is evolutionarily conserved across various species .
Glyoxalase-I is a metalloenzyme that catalyzes the conversion of the hemimercaptal adduct, formed spontaneously between methylglyoxal and reduced glutathione (GSH), into S-D-lactoylglutathione . This reaction is the first step in the glyoxalase pathway, which ultimately converts methylglyoxal into D-lactate, a less toxic compound .
The human recombinant form of Glyoxalase-I is produced using E. coli expression systems and is often tagged with a 6-His tag for purification purposes . The recombinant enzyme retains its activity and is used in various biochemical assays to study its function and regulation.
The glyoxalase pathway serves as an important line of defense against glycation and oxidative stress in living organisms. By maintaining steady-state levels of methylglyoxal and other reactive dicarbonyl compounds, Glyoxalase-I helps protect cells from the harmful effects of these reactive species .
Recombinant human Glyoxalase-I is widely used in research to understand its role in cellular metabolism and its potential implications in various diseases. For instance, elevated levels of methylglyoxal and impaired glyoxalase activity have been linked to diabetes, cancer, and neurodegenerative diseases . Therefore, studying Glyoxalase-I can provide insights into the mechanisms underlying these conditions and potentially lead to the development of therapeutic strategies.